BioCryst’s Drug For Zika Virus Shows Promise In Mice

(Reuters) – BioCryst Pharmaceuticals Inc said on Monday a dose of its experimental antiviral drug improved survival rates in mice infected with the Zika virus in a preclinical study.

Two doses of the drug, BCX443, were tested against a placebo and an oral antiviral called ribavarin for their effect on survival of immune-deficient mice infected with Zika.

Seven out of eight mice that received the “standard” dose survived but none of the other mice that received either a low dose, the placebo or ribavirin were alive after 28 days.

Zika virus A worker uses an electronic microscope to observe mosquitoes at “Grupo Avance” (Advance Group) laboratory where biologists are developing a possible Zika-repellent clothes detergent additive in Santiago, March 4, 2016. Reuters/Ivan Alvarado

The study was conducted at Utah

... read more at: http://www.medicaldaily.com/biocryst-pharmaceuticals-experimental-drug-zika-virus-376800

by